Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT03915444 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT03915444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03915444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
HonorHealth Research Institute
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2019
Completion date
January 23, 2023
Enrollment
42 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma